focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIlika Plc Regulatory News (IKA)

Share Price Information for Ilika Plc (IKA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 28.50
Bid: 28.00
Ask: 29.00
Change: 0.00 (0.00%)
Spread: 1.00 (3.571%)
Open: 28.50
High: 28.50
Low: 28.50
Prev. Close: 28.50
IKA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on fuel cell catalyst patent in Europe

13 Aug 2015 07:00

RNS Number : 9123V
Ilika plc
13 August 2015
 



13 August 2015

Ilika plc

("Ilika" or the "Company")

 

Update on fuel cell catalyst patent in Europe

 

Ilika (AIM: IKA), the accelerated materials innovation company, announces that the European Patent Office (EPO) has upheld Ilika's opposition to a fuel cell catalyst patent from Brookhaven Science Associates (BSA).

 

Certain claims of a granted European patent from Brookhaven Science Associates (BSA) might have impacted upon Ilika's freedom to operate its own granted European patent. BSA manages Brookhaven National Laboratory (BNL) on behalf of the United States Department of Energy (US DOE). BNL is a US national laboratory located in Upton, New York, on Long Island, primarily funded by the Office of Science of the US DOE.

 

Ilika had therefore filed an Opposition against the BSA patent in February 2013, and oral proceedings took place before the Opposition Division on 17th March 2015 at the European Patent Office (EPO) in Rijswijk, Netherlands. As a result of these proceedings, the BSA European patent was revoked. The EPO issued a notice on 8th August 2015 that the opposition proceedings were now terminated with revocation of the patent as the time limit had expired for filing an appeal against the decision to revoke the patent.

 

Ilika's patents underpin the product development work, which was supported by the Carbon Trust through the £150,000 equity investment Ilika announced in September 2012. The Carbon Trust invested in Ilika through its Polymer Fuel Cells Challenge programme to support the commercialization of Ilika's high performing electro-catalysts for use in fuel cell vehicles. As part of the Carbon Trust's technical and commercial evaluation of the technology, Ilika submitted performance data for assessment by independent experts demonstrating the performance and stability of the catalyst. The performance data was generated in industry standard tests of membrane electrode assemblies (MEA's) carried out at an independent fuel cell testing facility.

 

In December 2013, Ilika announced it had submitted positive cell performance data along with material samples for evaluation to three global OEM's. Initial trials were carried out by these OEM's in 2014 and Ilika continues to support evaluation trials by these three and other OEM's. The adoption rate of fuel cell technology has been historically difficult to predict and at present there is only a limited number of vehicles powered by fuel cells on the UK market. However, the first production Toyota Mirai models landed in Europe this week ahead of the official launch in September. The limited number of cars available in Britain is already sold out. The launch of this vehicle signals an increased focus by OEM's on cost-reduction of fuel cell technology with a view to enabling the mass market.

 

Commenting on this latest development, Graeme Purdy, Ilika CEO, said: "Ilika invests significantly in creating valuable intellectual property to underpin the growth of its business. Potentially competitive filings are monitored very closely and are challenged where appropriate. We welcome this development as we now enjoy freedom to operate our European patent in addition to our United States patent where there had never been such issues because of the different claims structures between the granted US patents of both BSA and Ilika. This positive outcome supports Ilika's commercialisation activities with interested OEM's."

 

 

  

 

 

For more information contact:

 

Ilika plc

www.ilika.com

Graeme Purdy, Chief Executive

Tel: 023 8011 1400

Steve Boydell, Finance Director

 

 

 

Numis Securities Limited

Tel: 020 7260 1000

Oliver Cardigan/ Adrian Trimmings /

 

James Black

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 / ilika@walbrookpr.com

Lianne Cawthorne (Media Enquiries)

Mob: 07584 391 303

Paul Cornelius (Investor Enquiries)

Mob: 07827 879460

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLFFFFTLIFLIE
Date   Source Headline
13th May 202410:16 amRNSPosting of Circular & Notice of General Meeting
10th May 20243:02 pmRNSResult of Placing
10th May 20247:00 amRNSProposed Placing and Open Offer & Notice of GM
26th Apr 20247:00 amRNSAgratas joins Goliath industrialisation programme
23rd Apr 20247:00 amRNSCapital Markets Day and Trading Update
27th Mar 20247:00 amRNSNotice of Capital Markets Day and Investor Q&A
23rd Jan 20247:00 amRNSHalf-year Report
15th Jan 20247:00 amRNS2024 Conference Schedule
14th Dec 20231:46 pmRNSAward of Share Options, Exercise of Options & TVR
13th Dec 20231:43 pmRNSHolding(s) in Company
6th Dec 20237:00 amRNSLithium-ion parity development milestone
24th Nov 20237:00 amRNSTrading Update, Notice of Results & Presentations
20th Nov 20237:00 amRNSKey Technology Development Milestone
9th Oct 20237:00 amRNSAward of Scale-up Grant Funding for Goliath
20th Sep 20233:20 pmRNSResult of AGM & Award of Executive Share Options
18th Aug 20237:00 amRNSPosting of Annual Report and Notice of AGM
4th Aug 20237:00 amRNSSigned agreement with Cirtec Medical
13th Jul 20237:00 amRNSFinal Results
16th Jun 20237:00 amRNSSenior appointment&conversion of preference shares
22nd May 20237:00 amRNSTrading Update & Notice of Results
11th May 20237:00 amRNSFirst Customer Shipments of Stereax M300 Batteries
26th Apr 20237:00 amRNSExercise of Options and Total Voting Rights
11th Apr 20237:00 amRNSFirst Customer Shipment of Stereax® Batteries
8th Mar 20234:35 pmRNSPrice Monitoring Extension
1st Mar 20237:00 amRNSAward of Share Options
31st Jan 202310:30 amRNSDirector/PDMR Shareholding
30th Jan 20232:05 pmRNSSecond Price Monitoring Extn
30th Jan 20232:00 pmRNSPrice Monitoring Extension
30th Jan 202311:05 amRNSSecond Price Monitoring Extn
30th Jan 202311:00 amRNSPrice Monitoring Extension
26th Jan 20232:05 pmRNSSecond Price Monitoring Extn
26th Jan 20232:00 pmRNSPrice Monitoring Extension
26th Jan 202311:05 amRNSSecond Price Monitoring Extn
26th Jan 202311:00 amRNSPrice Monitoring Extension
26th Jan 20239:05 amRNSSecond Price Monitoring Extn
26th Jan 20239:00 amRNSPrice Monitoring Extension
26th Jan 20237:00 amRNSAward of Grant Funding for Goliath
19th Jan 20237:00 amRNSHalf-year Report
16th Jan 20237:00 amRNSMOU signed with Cirtec Medical
9th Jan 20234:40 pmRNSSecond Price Monitoring Extn
9th Jan 20234:35 pmRNSPrice Monitoring Extension
28th Dec 20224:40 pmRNSSecond Price Monitoring Extn
28th Dec 20224:35 pmRNSPrice Monitoring Extension
28th Dec 20222:05 pmRNSSecond Price Monitoring Extn
28th Dec 20222:00 pmRNSPrice Monitoring Extension
19th Dec 20224:40 pmRNSSecond Price Monitoring Extn
19th Dec 20224:35 pmRNSPrice Monitoring Extension
16th Dec 20224:40 pmRNSSecond Price Monitoring Extn
16th Dec 20224:35 pmRNSPrice Monitoring Extension
21st Nov 20221:29 pmEQSIlika 'well positioned' to deliver battery product combination

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.